For Immediate Release |
17 January 2013 |
Alliance Pharma plc
TR-1: Notification of Major Interest in Shares
1. Identity of the issuer or the underlying issuer |
Alliance Pharma plc |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
|
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE |
x |
||
3. Full name of person(s) subject to the |
Aviva plc & its subsidiaries |
|||
4. Full name of shareholder(s) |
Registered Holder:
BNY (Nominees)Limited 212,570*
BNY Norwich Union Nominees Limited 3,433,941*
Chase (GA Group) Nominees Limited 19,527,011*
Chase Nominees Limited 532,329*
Vidacos Nominees Limited 157,711*
*denotes direct interest
Chase Nominees Limited 453,193
|
|||
5. Date of the transaction and date on |
15 January 2013 |
|||
6. Date on which issuer notified: |
16 January 2013 |
|||
7. Threshold(s) that is/are crossed or |
10% to <10% Change at Combined Interest Level |
|||
8. Notified details: |
|||||||||||
A: Voting rights attached to shares |
|||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
|||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights |
|||||||
Direct |
Direct |
Indirect |
Direct |
Indirect |
|||||||
Ordinary Shares |
24,316,755 |
24,316,755 |
24,316,755 |
23,863,562 |
453,193 |
9.79% |
0.19% |
||||
|
|||||||||||
|
|||||||||||
B: Qualifying Financial Instruments |
|||||||||||
Resulting situation after the triggering transaction |
|||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
|||||||
|
|
|
|
|
|||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
||||||
Resulting situation after the triggering transaction |
||||||
Type of financial |
Exercise price |
Expiration date |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights
|
|
|
|
|
|
|
Nominal |
Delta |
|
|
Total (A+B+C) |
|
Number of voting rights |
Percentage of voting rights |
24,316,755 |
9.98% |
9. Chain of controlled undertakings through which the voting rights and/or the |
||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See Section 4 |
|
11. Number of voting rights proxy holder will cease |
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
||
|
|
|
14. Contact name: |
Neil Whittaker, Aviva plc |
|
15. Contact telephone number: |
01603 684420 |
|